Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 6, Pages 1485-1490
Publisher
Oxford University Press (OUP)
Online
2013-02-05
DOI
10.1093/annonc/mds658
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
- (2012) Adam Brufsky et al. BREAST CANCER RESEARCH AND TREATMENT
- Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
- (2012) Jean-Yves Pierga et al. LANCET ONCOLOGY
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
- (2012) Christoph Thomssen et al. ONCOLOGY
- Pathologic Response to Short Intensified Taxane-free Neoadjuvant Chemotherapy in Patients with Highly Proliferative Operable Breast Cancer
- (2011) Christophe Le Tourneau et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
- (2011) Laura J. Esserman et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?
- (2010) M. Golshan et al. ANNALS OF SURGICAL ONCOLOGY
- Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment
- (2010) Helena R. Chang et al. CANCER
- Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features
- (2010) Ramachandran Venkitaraman Expert Review of Anticancer Therapy
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
- (2009) G. Frasci et al. ANNALS OF ONCOLOGY
- Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study
- (2009) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlook
- (2009) Zeina Nahleh MEDICAL ONCOLOGY
- Platinum-based chemotherapy in triple-negative breast cancer
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started